Back to Search

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Recruiting Phase 2 Interventional Study
Overweight Obesity
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
Eli Lilly and Company · Industry
Who this trial is looking for

This trial is looking for adults who are overweight or have obesity and do not have diabetes. It's important that participants don’t have certain heart conditions, issues with their pancreas, or are taking medications that haven’t been stable for at least three months.

Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

Trial Locations

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have …
Contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

317-615-4559

LillyTrials@Lilly.com

CONTACT

Physicians interested in becoming principal investigators please contact

clinical_inquiry_hub@lilly.com

CONTACT

NCT ID: NCT07589608 Source: ClinicalTrials.gov